Company profile
Viropro Inc.
OTC: VPRO · Healthcare · Biotechnology
#924 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 55
v0.1 · 5/100 weight · pillars only
↑ listing tenure, 3-yr revenue growth · ↓ market scale, Piotroski F
Methodology →Revenue TTM
$1.0M
Rev growth YoY (TTM)
+155.0%
Net income (FY)
-$1.0M
Employees
—
as of 2026-08-29
Market cap
$25.4k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$571.1k$571.1k2010
Net income-$1.0M-$1.0M2010
Operating income-$996.5k-$996.5k2010
Total assets$2.1M$2.1M2010
Liabilities$657.1k$657.1k2010
Equity$1.5M$1.5M2010
Revenue trend
FY2003 – FY2010 · USD
FY03
FY04
FY05
FY06
FY07
FY08
FY09
FY10
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Viropro Inc.’s revenue?
Viropro Inc. booked $571.1k in FY2010 revenue — among the slowest-growing Healthcare companies we track, at a -176.9% net margin.
Peers · Healthcare
Grapefruit USA, Inc.——Theralase Technologies Inc.37DErnexa Therapeutics Inc.43DVYNE Therapeutics Inc.38DTrevena, Inc.——Solana Company49DNeighbors
Santa Clara →Key facts
CEOMichelle Leanne Edythe Peake
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Jose, CA
ExchangeOTC: VPRO
Employees—
IPO date1995-04-20
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.